Key Points
PHILADELPHIA, Nov 11 (Reuters) - Novo Nordisk (NOVOb.CO) on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday...
Early data from the Danish drugmaker's Select trial released in August demonstrated that Wegovy, which has been shown to help patients lose an average of 15% of their weight, also reduced incidence of heart attack, stroke or death from heart disease by 20%...
Full results from the study, presented at the American Heart Association annual scientific meeting in Philadelphia and published in the New England Journal of Medicine, suggest the drug has other beneficial effects beyond the known health benefits from losing weight...
In the study of overweight and obese patients based on body mass index who had preexisting heart disease but not diabetes, Wegovy reduced the risk of non-fatal heart attack by 28%, non-fatal stroke by 7% and heart-related death by 15% compared to a placebo...
The study showed Wegovy to be safe and well-tolerated in line with previous semaglutide trials, Novo said.. Lange said he expected the company's application to have Wegovy's label updated to include the heart benefits to be approved in the U.S. in the first half of next year and in the EU in the second half..
You might be interested in
Wegovy reduces risk of heart attacks, strokes, and death by up to 20%, new study finds
08, Aug, 23A large global study found that weight-loss drug Wegovy reduced the risk of major cardiovascular issues. It could prompt insurers to cover the drug.
The Obesity Drug Revolution Just Got Real
08, Aug, 23Wegovy reduces risk of heart attack, stroke in study, paving way for greater insurance coverage
Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss
13, Nov, 23Novo Nordisk (NOVOb.CO) shares rose 3% on Monday as the market reacted to data the drugmaker presented over the weekend showing that the heart protective benefits of its popular obesity drug Wegovy are not solely due to weight loss.
Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks
08, Aug, 23In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss but has also shown a remarkable reduction in the risk of heart disease.
Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month
02, Nov, 23The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month, a senior executive said on Thursday.
What to know about Eli Lilly's new obesity drug
08, Nov, 23The U.S. Food and Drug Administration approved Eli Lilly's (LLY.N) keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's (NOVOb.CO) popular weight-loss therapy Wegovy.
Launches of Novo Nordisk's weight-loss drug Wegovy
23, Nov, 23Novo Nordisk (NOVOb.CO) is pushing ahead with the launches of weight-loss drug Wegovy in Europe and Japan, even as it struggles to keep up with demand.
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
03, Dec, 23Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines.